Table 2.
Initial, midpoint, and final values on outcomes by study group
| POWIR Group
|
FLEX Group
|
|||||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | Baseline | 6mo | 12mo | Baseline | 6mo | 12mo | P* | P† |
| Objectively measured outcomes | ||||||||
| Bench press 1RM (kg) | 46.8±13.2 | 49.4±15.3‡ | 50.0±16.2 | 44.6±11.3 | 42.2±12.0 | 43.8±13.0 | .01 | .03 |
| Leg press 1RM (kg) | 121.3±33.5 | 137.5±44.3‡ | 142.4±52.2 | 119.9±30.3 | 121.8±33.4 | 120.8±30.6 | .03 | .01 |
| Chair stand (s) | 12.1±2.47 | 10.9±1.9 | 10.3±1.83 | 11.4±1.61 | 11.7±1.8 | 10.6±1.61 | .07 | .09 |
| 4-m usual walk speed (m/s) | 1.31±0.16 | 1.21±0.19 | 1.39±0.18 | 1.20±0.23 | 1.07±0.27 | 1.29±0.29 | .97 | .37 |
| 4-m fast walk (m/s) | 1.98±0.26 | 1.67±0.31 | 2.06±0.31 | 1.88±0.32 | 1.67±0.29 | 2.07±0.31 | .13 | .31 |
| PPB | 10.9±1.1 | 11.4±0.82 | 11.5±0.72 | 10.6±1.7 | 10.9±1.4 | 11.2±1.6 | .88 | .92 |
| Self-report outcomes | ||||||||
| LLFDI | ||||||||
| Overall function | 68.7±9.6 | 69.7±10.7 | 70.0±9.4 | 75.6±19.1 | 73.4±18.7 | 74.4±18.3 | .36 | .21 |
| Basic upper-extremity function | 85.3±11.4 | 85.0±12.3 | 85.1±9.5 | 85.2±17.9 | 81.3±16.0 | 81.1±1.2 | .43 | .15 |
| Basic lower-extremity function | 81.6±13.8 | 82.7±17.2 | 82.8±14.1 | 83.9±20.5 | 83.6±20.7 | 85.4±18.9 | .68 | .40 |
| Advanced lower-extremity function | 63.5±14.5 | 65.3±12.8 | 65.3±13.1 | 69.8±22.4 | 67.6±22.4 | 69.8±21.9 | .32 | .26 |
| Disability limitation | 81.6±13.7 | 85.3±13.5 | 89.8±13.3 | 78.2±17.3 | 79.0±17.4 | 80.9±14.1 | .32 | .02 |
| EORTC QLQC30 | ||||||||
| Physical function | 87.5±14.3 | 92.2±11.7‡ | 93.3±9.0 | 89.7±15.3 | 82.4±20.1 | 86.7±20.7 | <.01 | <.01 |
| Schwartz Cancer Fatigue Scale | ||||||||
| Fatigue | 9.87±4.47 | 9.22±3.46 | 8.83±3.19 | 9.92±3.58 | 9.17±2.98 | 9.83±3.66 | .32 | .06 |
NOTE. Data are presented as unadjusted mean ± SD for participants who completed baseline and 6-month and 12-month follow-up or as otherwise indicated.
Abbreviations: EORTC, European Organization for Research and Treatment on Cancer; 1RM, 1 repetition maximum; QLQC30, Quality of Life Questionnaire.
P value for group × time interaction using all 3 time points from per protocol analysis adjusted for age and time since diagnosis.
P value for group × time interaction using all available time points from ITT analyses adjusted for age and time since diagnosis.
Group × time interaction is significant at the midpoint of the trial tested by planned comparisons between baseline and 6-month time points from per protocol analyses, adjusted for age and time since diagnosis, P<.05.